
BOLD Stock Forecast & Price Target
BOLD Analyst Ratings
Bulls say
Boundless Bio Inc. is strategically positioned in the oncology market by targeting a critical area of unmet need with its pioneering approach to address oncogene-amplified tumors through the use of extrachromosomal DNA (ecDNA). The potential of its lead candidate, BBI-355, as a toxicity-mitigated oral selective inhibitor of CHK1 supports a promising framework for enhanced efficacy, especially when leveraged in combination therapies. Additionally, while current valuations do not account for supplementary technologies, their successful development represents a potential upside, indicating significant long-term growth prospects for the company.
Bears say
Boundless Bio Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include potential delays in the clinical development of BBI-355, particularly in light of negative clinical data regarding its therapeutic window, and the possibility of failing to achieve regulatory approval. Additionally, slower-than-anticipated commercial uptake for BBI-355, combined with potential setbacks in other pipeline programs and the risk of medium- to long-term dilution, further complicate the company's financial prospects.
This aggregate rating is based on analysts' research of Boundless Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BOLD Analyst Forecast & Price Prediction
Start investing in BOLD
Order type
Buy in
Order amount
Est. shares
0 shares